Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Business Wire1 天
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
health.wusf.usf.edu1 天
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
STAT2 天
FDA approves schizophrenia drug that could alter how disorder is treated
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...
The Financial Express2 天
Bristol Myers gets USFDA nod for new type of schizophrenia drug
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
BioPharma Dive1 天
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
MM&M2 天
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.